Skip to main content

Advertisement

Table 4 Frequency of patients with at least one emergent adverse event (occurring in ≥5 % of patients): safety population

From: Chondroitin sulfate efficacy versus celecoxib on knee osteoarthritis structural changes using magnetic resonance imaging: a 2-year multicentre exploratory study

  Chondroitin sulfate (n = 97) Celecoxib (n = 97) p valuea
Events n (%) Events n (%)
Musculoskeletal and connective tissue disorders 72 37 (38.1) 59 38 (39.2) >0.999
 Arthralgia 19 14 (14.4) 14 11 (11.3) 0.669
 Back pain 17 16 (16.5) 5 5 (5.2) 0.019
 Pain in extremity 6 3 (3.1) 8 7 (7.2) 0.331
Infections and infestations 66 34 (35.1) 61 32 (33.0) 0.880
 Nasopharyngitis 28 19 (19.6) 18 15 (15.5) 0.572
Gastrointestinal disorders 37 27 (27.8) 44 29 (29.9) 0.874
 Dyspepsia 12 12 (12.4) 12 12 (12.4) 1.000
 Gastroesophageal reflux disease 5 5 (5.2) 5 5 (5.2) 1.000
Nervous system disorders 21 16 (16.5) 22 21 (21.6) 0.465
 Headache 15 12 (12.4) 10 10 (10.3) 0.821
Respiratory, thoracic, and mediastinal disorders 19 15 (15.5) 20 14 (14.4) >0.999
 Sinusitis 5 5 (5.2) 6 6 (6.2) >0.999
Injury, poisoning, and procedural complications 18 14 (14.4) 18 13 (13.4) >0.999
General disorders and administration site conditions 12 11 (11.3) 12 11 (11.3) 1.000
Skin and subcutaneous tissue disorders 3 3 (3.1) 11 11 (11.3) 0.049
Psychiatric disorders 4 4 (4.1) 9 9 (9.3) 0.250
Investigations 6 6 (6.2) 6 6 (6.2) 1.000
Surgical and medical procedures 8 5 (5.2) 8 6 (6.2) >0.999
Vascular disordersb 7 6 (6.2) 5 4 (4.1) 0.747
  1. Data shown are number of events or patients (%)
  2. aChi-squared test or Fisher’s exact test for proportions (%), bold indicates statistical significance
  3. bVascular disorders include mainly hypertension, varicose veins, and ulcers